Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Latest Articlesddd

The U.S. FDA Approved Oyster Point Pharma Inc Product TYRVAYA™ to Treat Dry Eye Disease

October 18, 2021 0

Oyster Point Pharma, Inc. The U.S. Food and Drug Administration (FDA) has approved the Oyster Point Pharma Inc …

Intellia Therapeutics and SparingVision Strategic Collaboration to Develop Novel Ocular Therapies. See Also: Crispr Therapeutics’ News is Good, Not Bad

October 14, 2021 0

Intellia Therapeutics and SparingVision Collaboration Intellia Therapeutics (NTLA) and SparingVision - a genomic medicine company developing …

Regenxbio Good News About RGX-314 for Diabetic Retinopathy

October 11, 2021 0

Regenxbio Announced Data from Phase 2 ALTITUDE Trial of RGX-314 for DR Regenxbio (RGNX) announced initial …

Don’t Miss the Enanta Pharmaceuticals Virtual Conference on October 19th – October 21st

October 11, 2021 0

Don’t Miss Enanta Pharmaceuticals Virtual Conference Enanta Pharmaceuticals (ENTA) – a clinical stage biotechnology company dedicated …

Denali Therapeutics: Positive Clinical Results and Regulatory Progress for Development Programs in ALS. See Also: NTLA Tumbling Today

October 8, 2021 0

Denali Therapeutics News Denali Therapeutics (DNLI) - a biopharmaceutical company developing a broad portfolio of product …

Intellia Therapeutics: Authorized to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for Hereditary Angioedema

October 6, 2021 0

Intellia Therapeutics Authorization of CTA for Phase 1/2 Study of NTLA-2002 Intellia Therapeutics (NTLA) announced the …

Atea Pharmaceuticals and Xenon Pharmaceuticals: Two Clinical-Stage Firms That Rallied Instead of Crashing Yesterday

October 5, 2021 0

Two Clinical-Stage Firms Rallied Yesterday On a day when the Stock Market was crushed, taking down …

Merck and Ridgeback Biotherapeutics Announced Successful Phase 3 Trial Results of Molnupiravir for Mild or Moderate COVID-19

October 1, 2021 0

Merck and Ridgeback Biotherapeutics COVID-19 News Merck (MRK) and Ridgeback Biotherapeutics today announced that molnupiravir (MK-4482, EIDD-2801) …

Valneva SE and Pfizer Inc Announce Further Positive Results in Preventing Lyme Disease

September 30, 2021 0

Valneva SE and Pfizer Inc Announced More Positive Trial Results of VLA15 for Lyme Disease What …

Reata Pharmaceuticals Plans to Submit Omaveloxolone NDA for Friedreich’s Ataxia in Q1 2022

September 30, 2021 0

Reata Pharmaceuticals to Submit Omaveloxolone for NDA in Early 2022 In a press release following the …

AstraZeneca Saphnelo Approved in Japan for Adult Patients with SLE

September 28, 2021 0

AstraZeneca Saphnelo Approved by Japanese Ministry of Health, Labor and Welfare Developed by AstraZeneca (AZN), Saphnelo …

The Time Has Come to Present Mirum Pharmaceuticals Inc

September 27, 2021 0

Mirum Pharmaceuticals Inc Mirum Pharmaceuticals Inc (MIRM) is a clinical-stage biopharmaceutical company focused on the development …

The World Health Organization Recommends Regeneron Pharmaceuticals Antibody Cocktail for COVID-19

September 24, 2021 0

Regeneron Welcomes the World Health Organization's Recommendation for Use of REGEN- COVTM to Treat COVID-19 The …

Can Excision BioTherapeutics Inc Cure HIV?!

September 24, 2021 0

Excision BioTherapeutics, Inc. IND Application for EBT-101 for HIV Accepted by the US FDA Excision BioTherapeutics, …

Encouraging News from Cassava Sciences

September 22, 2021 0

Cassava Sciences Announces Top-Line Clinical Data for Simulfilam Cassava Sciences Press Release Today Cassava Sciences (SAVA) …

Seagen Inc and Genmab Announce FDA Accelerated Approval for TIVDAK™ for Cervical Cancer

September 21, 2021 0

Seagen and Genmab Granted FDA Accelerated Approval for TIVDAK™ The U.S. FDA granted accelerated approval to …

Comprehensive Prohost Letter Issues

September 19, 2021 0

The Comprehensive Prohost Letter Issues The Comprehensive Prohost Letter Issues will constitute a chain of 7 …

Gilead Sciences: New Data Demonstrate Trodelvy Survival Benefit in Metastatic TNBC. See Also: Galapagos NV News

September 17, 2021 0

Gilead Sciences New Data from Trodelvy® Study Gilead Sciences (GILD) has recently announced new data from …

The U.S. FDA Accepted Intellia Therapeutics IND Application of NTLA-5001 for Acute Myeloid Leukemia

September 16, 2021 0

Intellia Therapeutics IND Application of NTLA-5001 for AML is Accepted by the US FDA NTLA-5001 is …

Why Jounce Therapeutics Stock is Outperforming Today

September 14, 2021 0

Jounce Therapeutics Jounce Therapeutics (JNCE) is a clinical-stage immunotherapy company developing therapies enabling the immune system …